Suria Investment Newsletter (SINLetter) is a free stock investment newsletter that highlights two publicly traded companies each month.

Astellas Pharma, based out of Japan, has agreed to pay Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) up to $295 million, including an immediate $165 million, for extending a deal with Regeneron to discover new drugs.  This deal will supersede the companies’...

According to Bloomberg, the Sanofi-Aventis (NYSE: SNY) last week to potentially purchase generic drugmaker Genzyme Corp. (NASDAQ: GENZ) is on track to become an actual bid, worth potentially as much as $18.7 billion. Last week, rumors were flying that...

If you recall Energizer (ENR) was an 'accidental' short as it was an outstanding short limit order placed quite a bit lower but triggered almost exactly at $60.00 on a gap up.  Since this is not the type of chart I like to short, I was thinking...

A look at the range-bound S&P 500.  (VIX and More also Bloomberg) Doug Kass, the market is facing “crosscurrents aplenty.”  (TheStreet) Bruce Berkowitz likes Morgan Stanley (MS).  (WSJ also InvestmentNews) Dr. Copper is back.  (MarketBeat) Now...

The strong results coming out of names like Cummins and other industrial giants are a sign that these businesses will lead the economy back to growth.

I’ve been talking and fearful of a move that would create buy signals, but would turn out to be a major whipsaw. This move has happened to the upside, gave great buy signals, but by the time the signals are starting to show up, the market used so...

Joachim Fels just isn’t giving in.Here’s what Morgan Stanley’s central-bank watcher had to say on his recent theme of inflation on Thursday — never mind...

Many wise observers and practitioners from Keynes and Triffin to Roubini and Grantham have thought of Gold as a barbarous relic. Let it be said, to the delight of Goldbugs, that I frown upon such a pejorative (at least for the duration of this post)....